NEW YORK – Inceptor Bio said on Wednesday that it has out-licensed its autologous CAR T-cell therapy for solid tumors, IB-T101, to Grit Bio in China.
Inceptor has granted Grit an exclusive license to develop, manufacture, and commercialize IB-T101 in China. The companies didn't disclose the financial details of their deal but noted that Inceptor will be eligible to receive milestone payments and royalties based on whether IB-T101 achieves certain response criteria. The firm will also use data generated in Grit's clinical trials in China to support regulatory submissions and development in other regions.
Inceptor, based in Morrisville, North Carolina, is developing IB-T101 as a treatment for clear cell renal cell carcinoma. IB-T101, which targets CD70, was developed using Inceptor's Outlast platform, which reprograms T cells to maintain stemness and effector function in the tumor microenvironment and make them more durable and effective at killing cancer cells.
The firm previously partnered with Dublin-based Avectas to support development of its CAR T-cell therapies. Inceptor, which launched in 2020, also owns a portfolio of companies focused on different cell therapy platforms and disease areas, including FastBack Bio, which focuses on developing CAR T-cell therapies for difficult-to-treat cancers, and Kincell Bio, a contract development and research organization that focuses on cell therapies.